Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead Sciences : Eli Lilly arthritis drug gets FDA nod for emergency use with remdesivir to treat COVID-19

11/19/2020 | 05:06pm EST

Nov 19 (Reuters) - The U.S. Food and Drug Administration on Thursday approved the emergency use of Eli Lilly and Co's arthritis drug, baricitinib, in combination with Gilead Sciences Inc's remdesivir, to treat COVID-19 patients.

Baricitinib, sold under the brand name of Olumiant, is an FDA-approved oral medication to treat moderately-to-severely active rheumatoid arthritis.

The approval was based on a review of the data from a clinical trial of hospitalized COVID-19 patients sponsored by the National Institute of Allergy and Infectious Diseases.

The trial showed an approximately one-day reduction in median recovery time for patients treated with the combination versus those treated with remdesivir.

The health regulator approved the drug in combination with remdesivir for treating suspected or laboratory confirmed COVID-19 in hospitalized adults and children two years of age or older requiring oxygen support. (Reporting by Mrinalika Roy in Bengaluru; Editing by Arun Koyyur)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ELI LILLY AND COMPANY 1.87% 206.14 Delayed Quote.22.09%
GILEAD SCIENCES, INC. -0.06% 66.94 Delayed Quote.14.90%
All news about GILEAD SCIENCES, INC.
01/21GILEAD SCIENCES : to Release Fourth Quarter and Full Year 2020 Financial Results..
BU
01/20GILEAD SCIENCES : Company - Francesco M. Marincola Joins Kite as Worldwide Head ..
AQ
01/19Gilead Sciences Up Nearly 7%, Best Performer in the Nasdaq 100 So Far Today -..
DJ
01/19STREET COLOR : SCOTUS Refuses to Hear Merck's Bid to Revive $2.5 Bln Patent Infr..
MT
01/19GILEAD SCIENCES : U.S. Supreme Court rebuffs Merck appeal in hepatitis C patent ..
RE
01/19GILEAD SCIENCES : U.S. Supreme Court rebuffs Merck appeal in hepatitis C patent ..
RE
01/19U.s. supreme court refuses to hear merck & co bid to revive $2.5 billion pate..
RE
01/19GILEAD SCIENCES : Francesco M. Marincola Joins Kite as Worldwide Head of Cell Th..
BU
01/19GILEAD SCIENCES : Morgan Stanley Upgrades Gilead Sciences to Overweight From Equ..
MT
01/15STRIDES PHARMA SCIENCE : Arm Gets US FDA Nod for HIV/AIDS Treatment Drug
MT
More news
Financials (USD)
Sales 2020 24 303 M - -
Net income 2020 39,3 M - -
Net Debt 2020 24 871 M - -
P/E ratio 2020 1 175x
Yield 2020 4,04%
Capitalization 83 911 M 83 911 M -
EV / Sales 2020 4,48x
EV / Sales 2021 4,29x
Nbr of Employees 11 800
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | MarketScreener
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 72,64 $
Last Close Price 66,94 $
Spread / Highest target 49,4%
Spread / Average Target 8,52%
Spread / Lowest Target -13,4%
EPS Revisions
Managers and Directors
NameTitle
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
William A. Lee Executive Vice President-Research
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.14.90%83 911
WUXI APPTEC CO., LTD.30.64%66 044
VERTEX PHARMACEUTICALS0.53%61 782
REGENERON PHARMACEUTICALS11.32%56 760
BEIGENE, LTD.44.94%34 148
GENMAB A/S7.31%28 292